Feasibility of a Therapeutic Intent Ontology

项目负责人/主要研究者（最后一名、第一名、中间名）：纳尔逊、斯图尔特J。 摘要 治疗意图可以被认为是开始治疗的原因，而不仅仅是一种疾病。 治疗，但治疗的背景是适当的。我们建议调查是否有可能 代表由美国FDA批准的结构化产品标签中药物适应症中的治疗意图。 使用标准受控词汇表和模型（上层），以正式的、可计算的方式与FDA进行沟通 应用本体）。如果成功的话，这种表示在临床决策支持中可能是非常宝贵的， 精准医疗，以及加深我们对药物用途的理解。我们建议研究 1000个RxNorm临床药物标签作为样本量，并基于该样本建立模型。然后通过 提供一个网络注释工具，我们将能够通过使用 内部制定的一套标准以及外部使用和审查。 OMB编号0925-0001/0002（2016年3月批准至2018年10月31日修订版）第1页续格式第页

Program Director/Principal Investigator (Last, First, Middle): Nelson, Stuart J. ABSTRACT Therapeutic intent can be thought of as the reason for commencing a therapy, not just a disease being treated, but the context in which the therapy is appropriate. We propose to investigate if it is possible to represent the therapeutic intent as seen in drug indications in the Structured Product Label approved by the FDA in a formal, computable manner, using standard controlled vocabularies and a model (an upper level application ontology). If successful, such a representation could be invaluable in clinical decision support, precision medicine, and in deepening our understanding of the uses of drugs. We propose studying the labels of 1000 RxNorm clinical drugs as a sample size, and basing a model on that sample. Then, by providing a web annotation tool, we would be able to evaluate the utility of the model by using both an internally developed set or criteria as well as outside use and review. OMB No. 0925-0001/0002 (Rev. 03/16 Approved Through 10/31/2018) Page 1 Continuation Format Page